Novartis AG (NYSE: NVS) Stock Competitors & Peer Comparison

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, LLY has a market cap of 1.2T. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while LLY trades at $1,265.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas LLY's P/E ratio is 38.95. In terms of profitability, NVS's ROE is +0.30%, compared to LLY's ROE of +0.93%. Regarding short-term risk, NVS is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for NVS.Check LLY's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, JNJ has a market cap of 653.4B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while JNJ trades at $273.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas JNJ's P/E ratio is 25.27. In terms of profitability, NVS's ROE is +0.30%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, NVS is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for NVS.Check JNJ's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, ABBV has a market cap of 457.5B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while ABBV trades at $262.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas ABBV's P/E ratio is 25.41. In terms of profitability, NVS's ROE is +0.30%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, NVS is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for NVS.Check ABBV's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, MRK has a market cap of 333.8B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while MRK trades at $149.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas MRK's P/E ratio is 42.11. In terms of profitability, NVS's ROE is +0.30%, compared to MRK's ROE of +0.07%. Regarding short-term risk, NVS is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for NVS.Check MRK's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, AZN has a market cap of 248.3B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while AZN trades at $163.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas AZN's P/E ratio is 17.29. In terms of profitability, NVS's ROE is +0.30%, compared to AZN's ROE of +0.22%. Regarding short-term risk, NVS is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for NVS.Check AZN's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, AMGN has a market cap of 229.5B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while AMGN trades at $437.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas AMGN's P/E ratio is 19.01. In terms of profitability, NVS's ROE is +0.30%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, NVS is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for NVS.Check AMGN's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, NVO has a market cap of 202.9B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while NVO trades at $46.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas NVO's P/E ratio is 11.37. In terms of profitability, NVS's ROE is +0.30%, compared to NVO's ROE of +0.59%. Regarding short-term risk, NVS is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for NVS.Check NVO's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, GILD has a market cap of 178.1B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while GILD trades at $146.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas GILD's P/E ratio is -367.79. In terms of profitability, NVS's ROE is +0.30%, compared to GILD's ROE of -0.16%. Regarding short-term risk, NVS is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for NVS.Check GILD's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, PFE has a market cap of 155.4B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while PFE trades at $28.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas PFE's P/E ratio is 8.94. In terms of profitability, NVS's ROE is +0.30%, compared to PFE's ROE of +0.05%. Regarding short-term risk, NVS is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for NVS.Check PFE's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, BMY has a market cap of 132.1B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while BMY trades at $67.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas BMY's P/E ratio is 10.90. In terms of profitability, NVS's ROE is +0.30%, compared to BMY's ROE of +0.47%. Regarding short-term risk, NVS is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for NVS.Check BMY's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, SNY has a market cap of 108B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while SNY trades at $45.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas SNY's P/E ratio is 9.80. In terms of profitability, NVS's ROE is +0.30%, compared to SNY's ROE of +0.06%. Regarding short-term risk, NVS is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for NVS.Check SNY's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, GSK has a market cap of 102.5B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while GSK trades at $52.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas GSK's P/E ratio is 11.05. In terms of profitability, NVS's ROE is +0.30%, compared to GSK's ROE of +0.24%. Regarding short-term risk, NVS is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for NVS.Check GSK's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, ZTS has a market cap of 31B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while ZTS trades at $76.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas ZTS's P/E ratio is 11.24. In terms of profitability, NVS's ROE is +0.30%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, NVS is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for NVS.Check ZTS's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, BIIB has a market cap of 30.9B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while BIIB trades at $218.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas BIIB's P/E ratio is 13.20. In terms of profitability, NVS's ROE is +0.30%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, NVS is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for NVS.Check BIIB's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVS's ROE is +0.30%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVS is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for NVS.Check HZNP's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, GRFS has a market cap of 6.6B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while GRFS trades at $8.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas GRFS's P/E ratio is 8.90. In terms of profitability, NVS's ROE is +0.30%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, NVS is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for NVS.Check GRFS's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while OGN trades at $13.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas OGN's P/E ratio is 4.08. In terms of profitability, NVS's ROE is +0.30%, compared to OGN's ROE of +0.23%. Regarding short-term risk, NVS is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for NVS.Check OGN's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, CELG-RI has a market cap of 224.5M. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while CELG-RI trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.30%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, NVS is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for NVS.Check CELG-RI's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, CTOR has a market cap of 67M. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while CTOR trades at $0.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas CTOR's P/E ratio is -1.53. In terms of profitability, NVS's ROE is +0.30%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, NVS is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for NVS.Check CTOR's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, SCLX has a market cap of 53.8M. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while SCLX trades at $6.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas SCLX's P/E ratio is -0.16. In terms of profitability, NVS's ROE is +0.30%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, NVS is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for NVS.Check SCLX's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, SCLXW has a market cap of 44.7M. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while SCLXW trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.30%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, NVS is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for NVS.Check SCLXW's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, MIRA has a market cap of 32.1M. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while MIRA trades at $0.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas MIRA's P/E ratio is -0.53. In terms of profitability, NVS's ROE is +0.30%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, NVS is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for NVS.Check MIRA's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, NVS's ROE is +0.30%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, NVS is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for NVS.Check BDSIW's competition here

Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVS stands at 293.9B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVS is priced at $158.81 on the NYSE, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVS currently has a P/E ratio of 17.79, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVS's ROE is +0.30%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVS is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for NVS.Check CRXT's competition here